explore -WSS

explore

author：entertainment 2025-10-01 21:37:23 - browse：1

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： RaDonda Vaught case: a double standard for nurses, physicians

explore

WSS

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Bacterial infection may be ‘key event’ in endometriosis, study says

Artificial intelligence advances fuel industry trying to preserve loved ones after death

AbbVie dramatically boosts its spending on lobbying

In new study, freeze

Pfizer's Covid pill remains 89% effective in final analysis, company says

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

A new study asks: Are we harming blood donors by taking blood?

How to save PrEP access — and even expand it

Van's Gluten Free Original Waffles recalled for possible wheat allergen

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA official pushes for dedicated emerging pathogens team

In Memoriam: Notable people who died in 2023

Organ transplantation is at a crossroads. Major reform is needed

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

hotspot

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Brain 'hot spot' may explain why African Americans feel greater pain

Listen: Biogen's messy board & Laronde's data problem

Make 'food is medicine' a key part of White House nutrition meeting

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Option Care buys Amedisys in $3.6 billion home care deal

explore

entertainment

knowledge

hotspot